Cardiac Biomarkers Aid in Differentiation of Kawasaki Disease from Multisystem Inflammatory Syndrome in Children Associated with COVID-19
- PMID: 38157048
- PMCID: PMC11213824
- DOI: 10.1007/s00246-023-03338-z
Cardiac Biomarkers Aid in Differentiation of Kawasaki Disease from Multisystem Inflammatory Syndrome in Children Associated with COVID-19
Abstract
Kawasaki disease (KD) and Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19 show clinical overlap and both lack definitive diagnostic testing, making differentiation challenging. We sought to determine how cardiac biomarkers might differentiate KD from MIS-C. The International Kawasaki Disease Registry enrolled contemporaneous KD and MIS-C pediatric patients from 42 sites from January 2020 through June 2022. The study population included 118 KD patients who met American Heart Association KD criteria and compared them to 946 MIS-C patients who met 2020 Centers for Disease Control and Prevention case definition. All included patients had at least one measurement of amino-terminal prohormone brain natriuretic peptide (NTproBNP) or cardiac troponin I (TnI), and echocardiography. Regression analyses were used to determine associations between cardiac biomarker levels, diagnosis, and cardiac involvement. Higher NTproBNP (≥ 1500 ng/L) and TnI (≥ 20 ng/L) at presentation were associated with MIS-C versus KD with specificity of 77 and 89%, respectively. Higher biomarker levels were associated with shock and intensive care unit admission; higher NTproBNP was associated with longer hospital length of stay. Lower left ventricular ejection fraction, more pronounced for MIS-C, was also associated with higher biomarker levels. Coronary artery involvement was not associated with either biomarker. Higher NTproBNP and TnI levels are suggestive of MIS-C versus KD and may be clinically useful in their differentiation. Consideration might be given to their inclusion in the routine evaluation of both conditions.
Keywords: Amino-terminal prohormone brain natriuretic peptide (NTproBNP); Cardiac biomarkers; Kawasaki disease (KD); Multisystem Inflammatory Syndrome in Children (MIS-C); Troponin I (TnI).
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Disclosures: Dr. Truong is an MPI on an NHLBI Pediatric Heart Network-Pfizer Partnership to Study COVID-19 Vaccine-Associated Myocarditis. Dr. Harahsheh serves as a scientific advisory board member of OP2 DRUGS (“OP2”) but this advisory position has no relevant disclosures for this manuscript.
Figures




Similar articles
-
Spectrum of Coronary Artery Involvement With Multisystem Inflammatory Syndrome in Children Versus Kawasaki Disease.J Am Heart Assoc. 2025 May 6;14(9):e037761. doi: 10.1161/JAHA.124.037761. Epub 2025 Apr 23. J Am Heart Assoc. 2025. PMID: 40265601 Free PMC article.
-
Differentiation of COVID-19-Associated Multisystem Inflammatory Syndrome From Kawasaki Disease With the Use of Cardiac Biomarkers.Can J Cardiol. 2023 Jun;39(6):815-823. doi: 10.1016/j.cjca.2022.11.012. Epub 2022 Dec 1. Can J Cardiol. 2023. PMID: 36462758 Free PMC article.
-
Diagnostic value of D-dimer in differentiating multisystem inflammatory syndrome in Children (MIS-C) from Kawasaki disease: systematic literature review and meta-analysis.Diagnosis (Berl). 2024 Feb 21;11(3):231-234. doi: 10.1515/dx-2024-0013. eCollection 2024 Aug 1. Diagnosis (Berl). 2024. PMID: 38374575
-
Six-Month Outcomes in the Long-Term Outcomes After the Multisystem Inflammatory Syndrome in Children Study.JAMA Pediatr. 2025 Mar 1;179(3):293-301. doi: 10.1001/jamapediatrics.2024.5466. JAMA Pediatr. 2025. PMID: 39804656
-
Corticosteroids for the treatment of Kawasaki disease in children.Cochrane Database Syst Rev. 2017 Jan 27;1(1):CD011188. doi: 10.1002/14651858.CD011188.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2022 May 27;5:CD011188. doi: 10.1002/14651858.CD011188.pub3. PMID: 28129459 Free PMC article. Updated.
Cited by
-
An Update on Multi-System Inflammatory Syndrome in Children.Curr Rheumatol Rep. 2025 Jan 30;27(1):16. doi: 10.1007/s11926-025-01182-z. Curr Rheumatol Rep. 2025. PMID: 39883190 Review.
-
Case Report: Two episodes of hyperinflammation in an infant consistent with multisystem inflammatory syndrome in children: recurrence or rather two different diseases?Front Pediatr. 2025 Jun 5;13:1559244. doi: 10.3389/fped.2025.1559244. eCollection 2025. Front Pediatr. 2025. PMID: 40538934 Free PMC article.
References
-
- McCrindle BW, et al., Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation, 2017. 135(17): p. e927–e999. - PubMed
-
- Newburger JW, et al., Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation, 2004. 110(17): p. 2747–71. - PubMed
-
- Organization, W.H. Multisystem Inflammatory Syndrome in Children and Adolescents with COVID-19. 2020. May 15 2020 [cited 2023 January 1]; Scientific Brief]. Available from: https://www.who.int/news-room/commentaries/detail/multisystem-inflammato....
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous